Vertex Pharmaceuticals Q3 Revenue Up 12%, Raises Full-Year 2026 Revenue Guidance
nashnova research
Vertex Pharmaceuticals posted Q3 revenue of $3.44 billion, up roughly 12% year-on-year and above consensus, then lifted its full-year sales guidance — but a sharp jump in R&D spending squeezed margins, and the flagship drug Trikafta's decline is now being offset by newer products ramping fast.
Revenue beat expectations — so why didn't profit follow?
Q3 revenue reached $3.44 billion, up about 12% year-on-year, beating the Street.
Non-GAAP EPS came in at $4.76, slightly below last year's $4.80 — revenue grew, yet earnings dipped.
This means → the pressure is on the cost side: total costs and expenses rose roughly 44% year-on-year to about $2.7 billion, far outpacing revenue growth.
In plain terms = the company is advancing multiple drug pipelines at once, spending faster than it earns, and R&D investment is eating into profit.
The guidance was raised — why isn't the market satisfied?
Vertex lifted its 2026 full-year revenue guidance from $13.1–13.2 billion to $13.15–13.25 billion.
Consensus stood at $13.28 billion — even the new upper bound falls about $30 million short.
At the same time, the combined non-GAAP R&D and SG&A expense guide jumped from $5.65–5.75 billion to $6.0 billion.
This means → revenue got a modest bump, but expenses got a big one — the profit window narrowed further.
The flagship drug is slowing — who fills the gap?
Trikafta/Kaftrio (a cystic fibrosis therapy and Vertex's largest product) saw sales drop roughly 8% year-on-year to about $2.4 billion — a clear plateau signal.
Alyftrek, also a cystic fibrosis treatment, surged about 186% to $705.8 million, becoming the most important growth driver.
This reflects a product "gear-shift" underway at Vertex — the older drug decelerates, the newer one picks up, and Alyftrek is already partially offsetting Trikafta's decline.
How are the two brand-new products performing?
Casgevy — a CRISPR-based gene therapy approved for sickle cell disease and transfusion-dependent beta thalassemia — posted Q3 revenue up roughly 487% to $99.2 million.
Journavx, a non-opioid pain drug, grew about 197% to $58.3 million.
In plain terms = both are growing at eye-catching rates, but combined revenue is under $160 million — tiny next to Trikafta's roughly $2.4 billion. They are still at the "seed stage," not yet big enough to carry the load.
Why did the cash pile shrink?
As of September 30, 2026, Vertex held $9.8 billion in cash, equivalents, and marketable securities — down from $12.3 billion at end-2025, a drop of roughly $2.5 billion.
This means → the drawdown mirrors the heavy R&D and business-development spending visible in the expense line.
The key question ahead: whether Alyftrek and the newer launches can sustain their ramp fast enough to restore margins — that will determine if this "cash burn" pays off.
市场有风险，内容仅供研究参考，不构成投资建议。